ACE2 is the SARS COV-2 receptor required for cell entry
NEJM Jwatch with references: Although offering a promising therapeutic and vaccine target against SARS-CoV-2, these new findings remind us that the viral pathogenesis of COVID-19 focuses on blood-pressure homeostasis mediated by the renin-angiotensin system (Future Virology 2010; 5:145). High risk for severe COVID-19 disease has been assumed to be driven largely by waning innate immunity that comes with advanced age, but younger patients with cardiovascular disease or hypertension may have unappreciated risk
